Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A 45-year-old man with dilated cardiomyopathy presented with acute leg pain and erythema suggestive of necrotising fasciitis. Initial surgical exploration revealed no necrosis and treatment for a soft tissue infection was started. Blood and tissue cultures unexpectedly grew a Gram-negative bacillus, subsequently identified by an automated broth microdilution phenotyping system as an extended-spectrum β-lactamase producing Escherichia coli. The patient was treated with a 3-week course of antibiotics (ertapenem followed by ciprofloxacin) and debridement for small areas of necrosis, followed by skin grafting. The presence of E. coli triggered investigation of both host and pathogen. The patient was found to have previously undiagnosed liver disease, a risk factor for E. coli soft tissue infection. Whole genome sequencing of isolates from all specimens confirmed they were clonal, of sequence type ST131 and associated with a likely plasmid-associated AmpC (CMY-2), several other resistance genes and a number of virulence factors.

Original publication

DOI

10.1136/bcr-2014-207200

Type

Journal article

Journal

BMJ Case Rep

Publication Date

19/10/2014

Volume

2014

Keywords

Amoxicillin-Potassium Clavulanate Combination, Anti-Bacterial Agents, Ciprofloxacin, Diagnosis, Differential, Drug Resistance, Multiple, Bacterial, Ertapenem, Escherichia coli, Escherichia coli Infections, Floxacillin, Follow-Up Studies, Genome, Bacterial, Gentamicins, Humans, Liver Diseases, Male, Meropenem, Middle Aged, Sequence Analysis, DNA, Soft Tissue Infections, Thienamycins, Treatment Outcome, Vancomycin, beta-Lactams